STRUCTURE THERAPEUTICS INC (GPCR)
US86366E1064 - ADR
STRUCTURE THERAPEUTICS INC
NASDAQ:GPCR (6/28/2024, 7:04:06 PM)
After market: 39.85 +0.58 (+1.48%)39.27
+0.13 (+0.33%)
Company Profile
Structure Therapeutics, Inc. is a clinical stage global biopharmaceutical company engaged in developing novel oral therapeutics to treat a wide range of chronic diseases with unmet medical needs. The company is headquartered in South San Francisco, California and currently employs 87 full-time employees. The company went IPO on 2023-02-03. The firm is focused on discovering and developing oral treatments for chronic metabolic and pulmonary conditions. The company develops oral small molecule therapeutics for the treatment of various diseases, including those impacting the metabolic, cardiovascular, and pulmonary systems. Its initial focus is on G-protein-coupled receptors as a therapeutic target class. The company is developing GSBR-1290, its oral small molecule product candidate targeting the validated glucagon-like-peptide-1 receptor for the treatment of type-2 diabetes mellitus and obesity. The company is also developing oral small molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases. Specifically, it is advancing ANPA-0073, its biased agonist, targeting the apelin receptor. The company is also developing LTSE-2578, an investigational oral small molecule LPA1R antagonist for the treatment of idiopathic pulmonary fibrosis.
Company Info
STRUCTURE THERAPEUTICS INC
611 Gateway Blvd Suite 223
South San Francisco CALIFORNIA
P: 16282299277
Employees: 87
Website: https://structuretx.com/
GPCR News
2 days ago - InvestorPlaceThe 3 Smartest Biotech Stocks to Buy With $5K Right NowWith global obesity numbers bursting at the seams, some of the smartest biotech stocks to buy are those with weight loss drugs.
13 days ago - The Motley FoolCould Structure Therapeutics Become the Next Novo Nordisk?Becoming the next Novo Nordisk is a long shot, but it's more likely than it sounds.
16 days ago - Investor's Business DailyGilead Sciences Jumps After Its Weight-Loss Drug Emerges From Under The RadarThe company just unveiled preclinical results from a test of its GLP-1 weight-loss drug.
19 days ago - The Motley FoolStructure Therapeutics Stock Could Rocket 87% Higher, According to 1 Wall Street Analyst. Is It Time to Buy?Analysts who follow the start-up drugmaker think its stock has a chance to soar, but that doesn't mean it's right for you.
20 days ago - Investor's Business DailySkye Bioscience Pivots To Obesity After Glaucoma Flop; Shares PlummetThe company is focusing on obesity treatment after its glaucoma drug failed.
21 days ago - The Motley FoolStructure Therapeutics' Stock Is Soaring on the Promise of Its Wegovy Competitor, but Is It a Buy?Structure Therapeutics has a long way to go before beating Wegovy.
GPCR Twits
Here you can normally see the latest stock twits on GPCR, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits:
